Overall survival longer compared with standard chemo for disease progression following platinum-based chemo and PD-1 or PD-L1 inhibitor<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, Feb. 18, 2021 (HealthDay News) — Overall survival is significantly longer in patients receiving enfortumab vedotin versus standard chemotherapy for previously treated locally advanced or metastatic urothelial cancer, according to a study published online Feb. 12 in the New England Journal of Medicine<\/em> to coincide with the American Society of Clinical Oncology annual Genitourinary Cancers Symposium, held virtually from Feb. 11 to 13.<\/p>\n Thomas Powles, M.D., from the University of London, and colleagues conducted a phase 3 trial of enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial carcinoma with disease progression during or after treatment with platinum-containing chemotherapy and a programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitor. Patients were randomly assigned to receive either enfortumab vedotin (301 participants) or chemotherapy (307 participants).<\/p>\n The researchers found that at a prespecified interim analysis (median follow-up of 11.1 months), overall survival was longer in the enfortumab vedotin group versus the chemotherapy group (12.88 versus 8.97 months; hazard ratio for death, 0.70). Similar results were seen for progression-free survival (5.55 versus 3.71 months; hazard ratio for progression or death, 0.62). The groups were similar with respect to incidence of treatment-related adverse effects and incidence of events of grade 3 or higher.<\/p>\n “The benefit of enfortumab vedotin was observed in most subgroups, including patients with liver metastasis,” the authors write.<\/p>\n The study was funded by Astellas Pharma US and Seagen, the manufacturers of enfortumab vedotin.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n